Q-omics provides the consensus-scored CDH15 profile across patient tissues and cancer cell-line models. CDH15 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CDH15 is differentially expressed in 13, with the highest sampling consensus in COAD. Additionally, CDH15 RNA expression shows 11,557 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRC, COAD, and TGCT as cancer lineages where CDH15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CDH15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CDH15 survival associations across molecular data types. CDH15 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CDH15 RNA expression–survival associations across cancer types. High CDH15 expression shows unfavorable associations in KIRC, ACC, KIRP, CESC and HNSC, but favorable associations in LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CDH15 RNA expression.
This table summarizes CDH15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 1. The strongest signals are observed in COAD for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for CDH15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CDH15 shows lower tumor expression in KIRP and higher tumor expression in COAD, THCA, LUAD, KIRC and BRCA. The COAD box plot shows higher CDH15 RNA expression in tumor versus normal tissue (log2 FC = +0.152, t-test p < 0.001).
This table shows molecular features associated with CDH15 in patient tissues and cancer cell lines. In patient samples, CDH15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, CDH15 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and SOFT_TISSUE.
